Malaria remains one of the most important parasitic diseases worldwide, with an estimated 249 million cases and 608 000 deaths in 2022.1 In July, 2022, the world's first malaria vaccine, RTS,S/AS01, was prequalified by WHO, paving the way for Gavi and ...
Ferrés M, Martínez-Valdebenito C, Henriquez C, et al. Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective study. Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7—In ...
Ferrés M, Martínez-Valdebenito C, Henriquez C, et al. Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective study. Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7—In ...
This study showed extended benefits of nirmatrelvir–ritonavir for reducing the risk of post-acute inpatient death as well as cardiovascular and respiratory complications among patients admitted to hospital with COVID-19. Further research is essential t...
In The Lancet Infectious Diseases, Huwen Wang and colleagues1 reported the outcomes of all adults admitted to hospital in Hong Kong with COVID-19 between March, 2022, and October, 2023. The study was a nationwide, retrospective cohort study, and examin...
In the wake of the COVID-19 pandemic, humanity experienced the emergence of another epidemic health threat in 2022. That threat came from human mpox (formerly known as monkeypox) virus—an agent that despite its discovery in 1958, has historically recei...
Nirsevimab substantially reduced infant hospitalisations for RSV-associated LRTI, severe RSV-associated LRTI requiring oxygen, and all-cause LRTI when given in real-world conditions. These findings offer policy makers and health authorities robust, rea...
Reducing cholera deaths is one of the principal goals of the Ending Cholera: A Global Roadmap to 2030 strategy.1 To direct interventions towards areas with highest needs and to monitor outbreak evolution, accurate and harmonised reporting of cholera-re...
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infection (LRTI), and mortality in infants, predominantly in those younger than 6 months.1 The predominant burden of severe illness occurs in full-term infants, althou...
Huang C, Peng Y, Zhang Y, et al. Deep dermatophytosis caused by Trichophyton rubrum. Lancet Infect Dis 2019; 19: 1380—The first sentence of the second paragraph of this Clinical Picture should have read, “Considering the unusual manifestation of this i...
High carbapenem use in targeting non-severe ECR Enterobacterales infections in US hospitals predates 2020 IDSA guidance and has persisted thereafter. Efforts to increase awareness and implementation of recommendations among clinicians to use carbapenem...
Participants who had tetravalent dengue purified inactivated vaccine prime and live-attenuated vaccine boost were unprotected against dengue virus-1 infection and further showed increased clinical, immunological, and transcriptomic evidence for inflamm...
The incidence of extended-spectrum β-lactamase-producing Enterobacterales infections has increased substantially in recent years, now accounting for approximately 15% of isolates causing infections.1 Understanding the management of these infections is ...
Dengue is an acute mosquito-borne illness that is caused by four different dengue viruses (serotypes 1–4). More than half the world's population lives at risk of dengue. Among the different approaches being explored to prevent dengue, an effective vacc...
SARS-CoV-2 viral clearance kinetics in symptomatic, vaccinated individuals accelerated substantially over 2 years of the pandemic, necessitating a change to how new SARS-CoV-2 antivirals are compared (ie, shortening the period of pharmacodynamic assess...
With almost 775 million COVID-19 cases reported worldwide and 67% of the global population vaccinated with a complete primary series of a COVID-19 vaccine, the deadly pace of the pandemic has slowed down substantially.1 Sculpted by infection, immunisat...